Uday B. Dandamudi

An Evaluation of the Drug Interaction Potential of Pazopanib, an Oral Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, Using a Modified Cooperstown 5+1 Cocktail in Patients With Advanced Solid Tumors

Brian C. Goh, Nandi J. Reddy, Uday B. Dandamudi et al. · Clinical Pharmacology & Therapeutics · 2010 · 82 citations

The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer

Geoffrey I. Shapiro, Richard C. Frank, Uday B. Dandamudi et al. · Cancer Chemotherapy and Pharmacology · 2011 · 31 citations · Full text

Nutrition, Advanced Cancer, Oncology +6

A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma

Uday B. Dandamudi, Musie Ghebremichael, Jeffrey A. Sosman et al. · Journal of Immunotherapy · 2013 · 26 citations

Il-2 Plus Bevacizumab, Urology, Genitourinary Cancer +15

Warfarin genotyping using three different platforms.

Joel A. Lefferts, Mary C. Schwab, Uday B. Dandamudi et al. · PubMed Central · 2010 · 16 citations · Full text

Genetic Testing, Genetic Epidemiology, Traditional Warfarin +21

A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group Study (CWGS).

Uday B. Dandamudi, Musie Ghebremichael, Jeffrey A. Sosman et al. · Journal of Clinical Oncology · 2010 · 13 citations

Il-2 Therapy, Immunology, Phase Ii Study +16